British Journal of Haematology最新文献_第7页

Low-dose iron chelation as anti-oxidative therapy in patients with sickle cell disease: A single-centre pilot study. 低剂量铁螯合作为镰状细胞病患者的抗氧化治疗：一项单中心试点研究

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-06 DOI: 10.1111/bjh.19943

Aafke E Gaartman, Boukje M Beuger, Lydian A de Ligt, Martijn Veldthuis, Hanke L Matlung, Joost C M Meijers, Casper G Schalkwijk, Koen de Heer, Jarom Heijmans, Rob van Zwieten, Bart J Biemond, Robin van Bruggen, Erfan Nur

引用次数: 0

To err is human … so how can we prevent all ABO-incompatible transfusions? 人非圣贤孰能无过，那么我们怎样才能预防abo血型不相容的输血呢？

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-04 DOI: 10.1111/bjh.19904

Nancy M Dunbar, Richard M Kaufman

引用次数: 0

Iron overload in hereditary spherocytosis: Are genetic factors the cause? 遗传性球形红细胞增多症的铁超载：是遗传因素引起的吗？

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-04 DOI: 10.1111/bjh.19941

Lucie Donaty, Muriel Giansily-Blaizot, Ivan Bertchansky, Séverine Cunat, Vincent Azoury, Perrine Mahe, Patricia Aguilar Martinez

引用次数: 0

Warning from heart: An unusual case report of isolated Rosai-Dorfman disease in an Asian 来自心脏的警告：一个罕见的病例报告孤立的罗赛-多夫曼病在亚洲。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-03 DOI: 10.1111/bjh.19913

Ming-Xuan Zhang, Bo-Wen Zhao, Bei Wang, Ji-Ling Zeng

引用次数: 0

Machine learning based on multiplatform tests assists in subtype classification of mature B-cell neoplasms 基于多平台测试的机器学习有助于成熟b细胞肿瘤的亚型分类。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-03 DOI: 10.1111/bjh.19934

Junwei Lin, Yafei Mu, Lingling Liu, Yuhuan Meng, Tao Chen, Xijie Fan, Jiecheng Yuan, Maoting Shen, Jianhua Pan, Yuxia Ren, Shihui Yu, Yuxin Chen

{"title":"Machine learning based on multiplatform tests assists in subtype classification of mature B-cell neoplasms","authors":"Junwei Lin, Yafei Mu, Lingling Liu, Yuhuan Meng, Tao Chen, Xijie Fan, Jiecheng Yuan, Maoting Shen, Jianhua Pan, Yuxia Ren, Shihui Yu, Yuxin Chen","doi":"10.1111/bjh.19934","DOIUrl":"10.1111/bjh.19934","url":null,"abstract":"<div>\u0000 \u0000 Mature B-cell neoplasms (MBNs) are clonal proliferative diseases encompassing over 40 subtypes. The WHO classification (morphology, immunology, cytogenetics and molecular biology) provides comprehensive diagnostic understandings. However, MBN subtyping relies heavily on the expertise of clinicians and pathologists, and differences in clinical experience can lead to variations in subtyping efficiency and consistency. Additionally, due to the diversity in genetic backgrounds, machine learning (ML) models constructed based on Western populations may not be suitable for Chinese MBN patients. To construct a highly accurate classification model suitable for Chinese MBN patients, we first developed an ML model based on next-generation sequencing (NGS) from Chinese MBN patients, with an accuracy of 0.719, which decreased to 0.707 after model feature selection. Another ML model based on NGS and tumour cell size had an accuracy of 0.715, which increased to 0.763 after model feature selection. Both models were more accurate than models constructed using Western MBN patient databases. Furthermore, by adding flow cytometry for CD5 and CD10, the accuracy reached 0.864, which further improved to 0.872 after model feature selection. These models are accessible via an open-access website. Overall, ML models incorporating multiplatform tests can serve as practical auxiliary tools for MBN subtype classification.\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 1","pages":"224-234"},"PeriodicalIF":5.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation 不适合异体造血干细胞移植的急性髓系白血病缓解期患者诱导后维持治疗的临床前景

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-02 DOI: 10.1111/bjh.19924

Kendra Sweet, Thomas Cluzeau

{"title":"Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation","authors":"Kendra Sweet, Thomas Cluzeau","doi":"10.1111/bjh.19924","DOIUrl":"10.1111/bjh.19924","url":null,"abstract":"For patients with acute myeloid leukaemia (AML) who achieve complete remission (CR) after induction therapy, subsequent allogeneic haematopoietic stem cell transplantation (allo-HSCT) reduces the risk of relapse. However, not all patients are eligible, warranting effective alternative maintenance strategies. Oral azacitidine is the only non-targeted therapy approved by both the United States (US) Food and Drug Administration and the European Medicines Agency for the maintenance or continued treatment of allo-HSCT-ineligible patients with AML achieving CR or CR with incomplete haematological recovery following induction chemotherapy. Midostaurin and histamine dihydrochloride are approved in Europe as maintenance therapy for AML in remission, and quizartinib is approved in the United States and Europe for the treatment and maintenance of patients with newly diagnosed FLT3-ITD AML. Barriers to maintenance treatment include limited clinical trial data informing appropriate patient and treatment selection, patient preference, financial burden and paucity of real-world data. This article discusses current maintenance treatment guidelines for patients with AML in remission but not proceeding to allo-HSCT and reviews clinical trial data for agents approved for use in remission. Ongoing studies of interest and considerations for future efforts are also discussed.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 1","pages":"61-68"},"PeriodicalIF":5.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer. 嵌合抗原受体-自然杀伤细胞免疫治疗癌症的进展与挑战。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-02 DOI: 10.1111/bjh.19939

Hind Rafei, Katayoun Rezvani

引用次数: 0

Contextualizing prophylactic red blood cell antigen matching in the lifelong care of sickle cell disease and thalassaemia patients 镰状细胞病和地中海贫血患者终身护理中预防性红细胞抗原匹配的背景研究

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-02 DOI: 10.1111/bjh.19878

Eric A. Gehrie, Garrett S. Booth

{"title":"Contextualizing prophylactic red blood cell antigen matching in the lifelong care of sickle cell disease and thalassaemia patients","authors":"Eric A. Gehrie, Garrett S. Booth","doi":"10.1111/bjh.19878","DOIUrl":"10.1111/bjh.19878","url":null,"abstract":"Alloimmunization to minor red blood cell antigens has been linked to patient morbidity and mortality, especially among people living with sickle cell disease and transfusion-dependent thalassaemia. Prophylactic antigen matching is commonly used to prevent alloimmunization, but the evidence supporting this common practice is very limited. The report by Wolf et al. summarizes the latest literature on this topic and importantly finds that there is insufficient evidence to recommend prophylactic extended antigen matching (beyond ABO, RhD, RhCcEe and K). In an era of chronic blood shortages, this approach may help to assure patient access to elective surgery and cellular therapies, while preserving the supply of extensively antigen-matched red cells for patients with specific needs.Commentary on: Wolf et al. Red cell specifications for blood group matching in patients with haemoglobinopathies: An updated systematic review and clinical practice guideline from the International Collaboration for Transfusion Medicine Guidelines. Br J Haematol 2025; 206:94-108.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 1","pages":"382-384"},"PeriodicalIF":5.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19878","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatitis E virus infection after CAR T-cell treatment: An important complication in patients already facing significant health challenges. CAR - t细胞治疗后戊型肝炎病毒感染：已经面临重大健康挑战的患者的一个重要并发症

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-02 DOI: 10.1111/bjh.19931

Vincent Mallet, Harrys A Torres

引用次数: 0

Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM. 骨髓瘤定义事件为SLiM的多发性骨髓瘤患者的自体干细胞移植。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-29 DOI: 10.1111/bjh.19936

Iuliana Vaxman, Shaji Kumar, Inbar Cohen, Shai Simony, Angela Dispenzieri, Francis Buadi, David Dingli, Eli Muchtar, Prashant Kapoor, William Hogan, Suzanne Hayman, Nelson Leung, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Morie Gertz

{"title":"Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM.","authors":"Iuliana Vaxman, Shaji Kumar, Inbar Cohen, Shai Simony, Angela Dispenzieri, Francis Buadi, David Dingli, Eli Muchtar, Prashant Kapoor, William Hogan, Suzanne Hayman, Nelson Leung, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Morie Gertz","doi":"10.1111/bjh.19936","DOIUrl":"https://doi.org/10.1111/bjh.19936","url":null,"abstract":"In 2014, the International Myeloma Working Group (IMWG) updated the criteria for diagnosing myeloma and added three additional criteria to the traditional Calcium elevation, Renal impairment, Anemia, Bone disease (CRAB) criteria, called the Sixty % marrow plama cells, Light chain ratio >60, Mri demonstates lytic lesions (SLiM) criteria (clonal bone marrow plasma cells ≥60%, involved to uninvolved free light chain ratio (FLCr) ≥100 and >1 focal lesion on magnetic resonance imaging (MRI)). We report on the outcomes of 30 patients who underwent autologous stem cell transplantation (ASCT) where therapy was initiated solely based on SLiM criteria and compared them to a matched cohort of 60 patients whose myeloma-defining event was CRAB. The SLiM cohort had a shorter median time to neutrophil (15 vs. 16 days, p = 0.049) and platelet (15 vs. 17 days, p = 0.0004) engraftment. The 36-month overall survival (OS) was 100% in the SLiM group and 93.27% in the control group (95% CI 83.06%-97.42%), with a trend towards longer OS in the SLiM cohort (p = 0.065). The 36-month progression-free survival (PFS) was 91.61% in the SLiM (95% CI 69.93%-97.87%) and 65.95% in the control group (95% CI 52.31%-76.53%). There was no difference in the PFS between the cohorts (p = 0.414). ASCT is efficacious and safe in MM patients transplanted only due to SLIM criteria. Early intervention in this asymptomatic cohort did not appear to result in deeper responses or better PFS compared to outcomes in symptomatic patients.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0